New sPCR Technology Runs on Standard Devices
|
By LabMedica International staff writers Posted on 24 Apr 2017 |

Image: A comparison of analytical PCR procedures (Photo courtesy of Scientific Reports).
Synergistic PCR (sPCR), a new method of DNA analysis developed for use on a new high-speed assay device, can also be carried out on widely available laboratory real-time PCR (qPCR) instruments and does not require calibration.
While developing a record high-speed genetic research tool, Curiosity Diagnostics (CD; Warsaw, Poland), a spinoff company of the Warsaw Institute of Physical Chemistry of the Polish Academy of Sciences (IPC PAS) and part of the Scope Fluidics group, has developed the new sPCR method, which combines key advantages of the two currently most used methods.
"The DNA assay technique we propose was born during the development of the innovative PCR|ONE analytical instrument, which can be used to test the genetic code in only 7 minutes. This is more than 10-fold shorter time than is required in classic solutions," said Prof. Piotr Garstecki (IPC PAS, CD).
PCR is used both to detect specific DNA fragments and to estimate the original amount of genetic material. In quantitative PCR (qPCR) measurements are usually carried out using real-time PCR – an analogue technique. Due to the sensitivity of PCR to even single particles of impurities, qPCR requires careful, continuous calibration. Conversely, in digital PCR (dPCR) there is no need to calibrate the device, however, because of the need to conduct a large number of reactions in parallel, the testing equipment is expensive and is not as common in laboratories as the analogue apparatus.
sPCR combines the most important advantages of analogue and digital methods to obtain reliable measurements: it is sufficient to dilute a sample into only a dozen or at most several dozen partitions, and calibration is not required.
"A small number of partitions, characteristic of our technique, are of specific practical significance. It means that to perform the analysis all that is needed is the standard well plate format used in popular analogue PCR devices," said Pawel Debski, an IPC PAS PhD student who developed the sPCR method with Curiosity Diagnostics.
Also due to a small number of sample partitions, the sPCR technique is easier to perform and slightly faster than digital variants. Compared to analogue techniques, however, more reagents are required, and so it will not replace the analogue variant. Nevertheless, sPCR could be a valuable addition, as it requires no calibration and so will allow laboratory staff to independently and regularly check the correctness of analogue measurements.
sPCR was developed as an integral component of PCR|ONE, an innovative device designed for rapid DNA analysis. In standard PCR machines, relatively slow heat diffusion between the sample and an adjacent large block of alternately heated or cooled material is used to heat and cool the genetic material. In PCR|ONE, infrared radiation is used to heat the sample rapidly. The diffusion cooling mechanism has also been modified: the block used for this purpose is smaller than in conventional instruments and it is maintained at a constant, strictly controlled temperature. As a result of the technical and analytical improvements, the currently being tested prototypes of PCR|ONE are able to complete DNA assays in less than 15 minutes, and the PCR itself takes only 7 minutes. The first PCR|ONE devices are expected to be commercially available in 2-3 years.
"Our DNA testing technique has been patented. However, we want to emphasize the freedom of using it for non-commercial purposes," said Prof. Garstecki.
The study, by Debski PR et al, was published March 22, 2017, in the journal Scientific Reports.
While developing a record high-speed genetic research tool, Curiosity Diagnostics (CD; Warsaw, Poland), a spinoff company of the Warsaw Institute of Physical Chemistry of the Polish Academy of Sciences (IPC PAS) and part of the Scope Fluidics group, has developed the new sPCR method, which combines key advantages of the two currently most used methods.
"The DNA assay technique we propose was born during the development of the innovative PCR|ONE analytical instrument, which can be used to test the genetic code in only 7 minutes. This is more than 10-fold shorter time than is required in classic solutions," said Prof. Piotr Garstecki (IPC PAS, CD).
PCR is used both to detect specific DNA fragments and to estimate the original amount of genetic material. In quantitative PCR (qPCR) measurements are usually carried out using real-time PCR – an analogue technique. Due to the sensitivity of PCR to even single particles of impurities, qPCR requires careful, continuous calibration. Conversely, in digital PCR (dPCR) there is no need to calibrate the device, however, because of the need to conduct a large number of reactions in parallel, the testing equipment is expensive and is not as common in laboratories as the analogue apparatus.
sPCR combines the most important advantages of analogue and digital methods to obtain reliable measurements: it is sufficient to dilute a sample into only a dozen or at most several dozen partitions, and calibration is not required.
"A small number of partitions, characteristic of our technique, are of specific practical significance. It means that to perform the analysis all that is needed is the standard well plate format used in popular analogue PCR devices," said Pawel Debski, an IPC PAS PhD student who developed the sPCR method with Curiosity Diagnostics.
Also due to a small number of sample partitions, the sPCR technique is easier to perform and slightly faster than digital variants. Compared to analogue techniques, however, more reagents are required, and so it will not replace the analogue variant. Nevertheless, sPCR could be a valuable addition, as it requires no calibration and so will allow laboratory staff to independently and regularly check the correctness of analogue measurements.
sPCR was developed as an integral component of PCR|ONE, an innovative device designed for rapid DNA analysis. In standard PCR machines, relatively slow heat diffusion between the sample and an adjacent large block of alternately heated or cooled material is used to heat and cool the genetic material. In PCR|ONE, infrared radiation is used to heat the sample rapidly. The diffusion cooling mechanism has also been modified: the block used for this purpose is smaller than in conventional instruments and it is maintained at a constant, strictly controlled temperature. As a result of the technical and analytical improvements, the currently being tested prototypes of PCR|ONE are able to complete DNA assays in less than 15 minutes, and the PCR itself takes only 7 minutes. The first PCR|ONE devices are expected to be commercially available in 2-3 years.
"Our DNA testing technique has been patented. However, we want to emphasize the freedom of using it for non-commercial purposes," said Prof. Garstecki.
The study, by Debski PR et al, was published March 22, 2017, in the journal Scientific Reports.
Latest Molecular Diagnostics News
- AI Tool Improves Long-Read Detection of Cancer Mutations
- FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
- Blood Gene Expression Fluctuates More Than Expected Over Time
- Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
- Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
- Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
- Portable Rapid Test Aims to Detect Ebola at Point of Care
- New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
- Point-of-Care Molecular Technology Promises Transformative Shift in Oncology
- Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
- Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
- New Biomarker Helps Guide Combination Therapy for Treatment-Resistant Breast Cancer
- Blood-Based Gene Expression Test Detects Early Pancreatic Cancer
- Blood-Based Biomarker Panel Outperforms Existing Liver Disease Tests
- Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
- HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
Channels
Clinical Chemistry
view channel
Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
Accurate diabetes detection is essential because early identification guides timely management, yet test performance can vary in people with hemoglobin variants such as sickle cell trait.... Read more
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








